We provide preclinical assay services using human-derived, target-specific next-generation in vitro tumor models.
By incorporating human functional vasculature and tumor microenvironment, we generate clinically translatable drug efficacy, mechanism of action and toxicity profiles — reducing attrition risk and accelerating candidate selection.
What sets us apart
Prediction: Target-specific tumor models associated with relevant readouts
Innovation: Human-derived in vitro functional tumor microenvironment
Validation: Aligned with in vivo and clinical outcomes